Published in J Neurosci on April 06, 2011
11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action. Physiol Rev (2013) 1.60
Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology. Biol Psychiatry (2013) 1.28
11β-Hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and function defects. J Clin Invest (2013) 0.97
Integrating transcriptomics with metabolic modeling predicts biomarkers and drug targets for Alzheimer's disease. PLoS One (2014) 0.81
Cognitive and Disease-Modifying Effects of 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibition in Male Tg2576 Mice, a Model of Alzheimer's Disease. Endocrinology (2015) 0.77
Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem(TM) ). Br J Pharmacol (2016) 0.75
Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther (2004) 1.33
Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J Neurosci (2007) 1.32
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor. J Med Chem (2008) 1.30
A-366833: a novel nicotinonitrile-substituted 3,6-diazabicyclo[3.2.0]-heptane alpha4beta2 nicotinic acetylcholine receptor selective agonist: Synthesis, analgesic efficacy and tolerability profile in animal models. Biochem Pharmacol (2007) 1.27
Liver-specific knockdown of JNK1 up-regulates proliferator-activated receptor gamma coactivator 1 beta and increases plasma triglyceride despite reduced glucose and insulin levels in diet-induced obese mice. J Biol Chem (2007) 1.24
Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes. J Med Chem (2004) 1.24
Effects of substitution on 9-(3-bromo-4-fluorophenyl)-5,9-dihydro-3H,4H-2,6-dioxa-4- azacyclopenta[b]naphthalene-1,8-dione, a dihydropyridine ATP-sensitive potassium channel opener. J Med Chem (2006) 1.23
Rescue of infralimbic mGluR2 deficit restores control over drug-seeking behavior in alcohol dependence. J Neurosci (2013) 1.22
A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Mol Endocrinol (2003) 1.17
Hepatic knockdown of mitochondrial GPAT1 in ob/ob mice improves metabolic profile. Biochem Biophys Res Commun (2006) 1.13
Proprotein convertase activation of aggrecanases in cartilage in situ. Arch Biochem Biophys (2008) 1.12
Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: relevance for neuropsychiatric disorders. Behav Brain Res (2008) 1.06
Effect of analgesic therapy on clinical outcome measures in a randomized controlled trial using client-owned dogs with hip osteoarthritis. BMC Vet Res (2012) 1.06
In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease. J Pharmacol Exp Ther (2010) 0.98
Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties. CNS Neurosci Ther (2008) 0.96
Identification and preliminary characterization of a potent, safe, and orally efficacious inhibitor of acyl-CoA:diacylglycerol acyltransferase 1. J Med Chem (2012) 0.94
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists. J Med Chem (2008) 0.92
Mice expressing the Swedish APP mutation on a 129 genetic background demonstrate consistent behavioral deficits and pathological markers of Alzheimer's disease. Brain Res (2009) 0.91
Nicotinic acetylcholine receptor agonists: a potential new class of analgesics. Curr Top Med Chem (2004) 0.90
Antidepressant-like effect of D(2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test. Neuropsychopharmacology (2005) 0.89
Effects of a positive allosteric modulator of group II metabotropic glutamate receptors, LY487379, on cognitive flexibility and impulsive-like responding in rats. J Pharmacol Exp Ther (2010) 0.89
The scopolamine model as a pharmacodynamic marker in early drug development. Psychopharmacology (Berl) (2011) 0.89
Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther (2012) 0.88
Inhibitors of GlyT1 affect glycine transport via discrete binding sites. Mol Pharmacol (2008) 0.88
Effects of antipsychotics and selective D3 antagonists on PPI deficits induced by PD 128907 and apomorphine. Behav Brain Res (2007) 0.88
Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11beta-hydroxysteroid dehydrogenase type 1 inhibitors. J Med Chem (2007) 0.88
Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. J Med Chem (2006) 0.88
Potentiation of analgesic efficacy but not side effects: co-administration of an α4β2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats. Biochem Pharmacol (2011) 0.88
Effects of histamine H3 receptor antagonists in two models of spatial learning. Behav Brain Res (2004) 0.88
Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists. Curr Pharm Des (2010) 0.87
Vogel conflict test: sex differences and pharmacological validation of the model. Behav Brain Res (2010) 0.86
Synthesis and SAR of highly potent dual 5-HT1A and 5-HT1B antagonists as potential antidepressant drugs. Bioorg Med Chem Lett (2005) 0.85
Assessment of pharmacology and potential anti-obesity properties of H3 receptor antagonists/inverse agonists. Expert Opin Investig Drugs (2005) 0.85
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia. J Med Chem (2008) 0.85
Antidiabetic activity of passive nonsteroidal glucocorticoid receptor modulators. J Med Chem (2005) 0.85
Enhancement of prepulse inhibition of startle in mice by the H3 receptor antagonists thioperamide and ciproxifan. Behav Brain Res (2004) 0.85
Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.84
Selective alpha7 nicotinic acetylcholine receptor activation regulates glycogen synthase kinase3beta and decreases tau phosphorylation in vivo. Brain Res (2009) 0.84
Delivery of RNAi reagents in murine models of obesity and diabetes. J RNAi Gene Silencing (2006) 0.83
2,4-diaminopyrimidine derivatives as potent growth hormone secretagogue receptor antagonists. J Med Chem (2006) 0.83
In-vivo histamine H3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer's disease. Neuropharmacology (2010) 0.83
Preclinical evaluation of non-imidazole histamine H3 receptor antagonists in comparison to atypical antipsychotics for the treatment of cognitive deficits associated with schizophrenia. Int J Neuropsychopharmacol (2012) 0.83
Rapamycin analogs with reduced systemic exposure. Bioorg Med Chem Lett (2005) 0.83
Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonists. J Med Chem (2006) 0.83
Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs. Brain Res (2005) 0.82
Structural abnormalities revealed by magnetic resonance imaging in rats prenatally exposed to methylazoxymethanol acetate parallel cerebral pathology in schizophrenia. Synapse (2010) 0.82
Synthesis and structure-activity relationships of 3,8-diazabicyclo[4.2.0]octane ligands, potent nicotinic acetylcholine receptor agonists. J Med Chem (2006) 0.82
Orally active thrombin inhibitors. Part 2: optimization of the P2-moiety. Bioorg Med Chem Lett (2006) 0.82
Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activity. Biochem Pharmacol (2007) 0.82
Behavioral characterization of a mutant mouse strain lacking D-amino acid oxidase activity. Behav Brain Res (2010) 0.81
An 80-amino acid deletion in the third intracellular loop of a naturally occurring human histamine H3 isoform confers pharmacological differences and constitutive activity. J Pharmacol Exp Ther (2007) 0.81
D-Phe-Pro-Arg type thrombin inhibitors: unexpected selectivity by modification of the P1 moiety. Bioorg Med Chem Lett (2003) 0.81
Loss of functional neuronal nicotinic receptors in dorsal root ganglion neurons in a rat model of neuropathic pain. Neurosci Lett (2004) 0.81
H3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization. Psychopharmacology (Berl) (2003) 0.80
Selective antagonism of the hepatic glucocorticoid receptor reduces hepatic glucose production. Metabolism (2006) 0.80
ABT-594 improves performance in the 5-choice serial reaction time task under conditions of increased difficulty, sub-chronic dosing, and in poorly-performing subjects. Pharmacol Biochem Behav (2010) 0.80
Synthesis of purines and other fused imidazoles from acyclic amidines and guanidines. Org Lett (2005) 0.80
The novel calpain inhibitor A-705253 prevents stress-induced tau hyperphosphorylation in vitro and in vivo. Neuropharmacology (2012) 0.79
Effects of α7 nicotinic acetylcholine receptor agonists on antipsychotic efficacy in a preclinical mouse model of psychosis. Psychopharmacology (Berl) (2011) 0.79
Modeling of relationships between pharmacokinetics and blockade of agonist-induced elevation of intraurethral pressure and mean arterial pressure in conscious dogs treated with alpha(1)-adrenoceptor antagonists. J Pharmacol Exp Ther (2002) 0.79
Chronic treatment with either dexfenfluramine or sibutramine in diet-switched diet-induced obese mice. Endocrine (2006) 0.79
Lack of efficacy of melanin-concentrating hormone-1 receptor antagonists in models of depression and anxiety. Eur J Pharmacol (2006) 0.79
Rigidified 2-aminopyrimidines as histamine H4 receptor antagonists: effects of substitution about the rigidifying ring. Bioorg Med Chem Lett (2010) 0.79
Effect of dopamine D3 antagonists on PPI in DBA/2J mice or PPI deficit induced by neonatal ventral hippocampal lesions in rats. Neuropsychopharmacology (2005) 0.79
PARP inhibitors attenuate chemotherapy-induced painful neuropathy. J Peripher Nerv Syst (2012) 0.79
Hepatic knockdown of stearoyl-CoA desaturase 1 via RNA interference in obese mice decreases lipid content and changes fatty acid composition. Front Biosci (2007) 0.79
Discriminative-stimulus effects of NS9283, a nicotinic α4β2* positive allosteric modulator, in nicotine-discriminating rats. Psychopharmacology (Berl) (2013) 0.79
Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists. J Med Chem (2007) 0.79
Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dihydro-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolines. J Med Chem (2003) 0.79
Effects of ATP-sensitive K+ channel openers and tolterodine on involuntary bladder contractions in a pig model of partial bladder outlet obstruction. Neurourol Urodyn (2003) 0.78
Structure-activity relationship of a novel class of naphthyl amide KATP channel openers. Bioorg Med Chem Lett (2003) 0.78
Differential effects of Vitamin D analogs on bone formation and resorption. J Steroid Biochem Mol Biol (2005) 0.78
Design and synthesis of novel potent and selective integrin alphanubeta3 antagonists--novel synthetic routes to isoquinolinone, benzoxazinone, and quinazolinone acetates. Bioorg Med Chem Lett (2007) 0.78
Synthesis and structure-activity studies on N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an imidazole-containing alpha(1A)-adrenoceptor agonist. J Med Chem (2004) 0.78
The drug-induced helplessness test: an animal assay for assessing behavioral despair in response to neuroleptic treatment. Psychopharmacology (Berl) (2006) 0.77
Design and synthesis of 1,5- and 2,5-substituted tetrahydrobenzazepinones as novel potent and selective integrin alphaVbeta3 antagonists. Bioorg Med Chem (2003) 0.77
Structure-activity studies of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder. J Med Chem (2007) 0.77